United States - English - NLM (National Library of Medicine)

genentech, inc. - rituximab (unii: 4f4x42syq6) (rituximab - unii:4f4x42syq6), hyaluronidase (human recombinant) (unii: 743quy4vd8) (hyaluronidase (human recombinant) - unii:743quy4vd8) - rituximab 120 mg in 1 ml - rituxan hycela is indicated for the treatment of adult patients with: - relapsed or refractory, follicular lymphoma as a single agent. - previously untreated follicular lymphoma in combination with first line chemotherapy and, in patients achieving a complete or partial response to rituximab in combination with chemotherapy, as single-agent maintenance therapy. - non-progressing (including stable disease), follicular lymphoma as a single agent after first-line cyclophosphamide, vincristine, and prednisone (cvp) chemotherapy. rituxan hycela is indicated for the treatment of adult patients with previously untreated diffuse large b-cell lymphoma in combination with cyclophosphamide, doxorubicin, vincristine, prednisone (chop) or other anthracycline-based chemotherapy regimens. rituxan hycela is indicated, in combination with fludarabine and cyclophosphamide (fc), for the treatment of adult patients with previously untreated and previously treated cll. - initiate treatment with rituxan hycela only after patients

United States - English - NLM (National Library of Medicine)

genentech, inc. - rituximab (unii: 4f4x42syq6) (rituximab - unii:4f4x42syq6) - rituximab 10 mg in 1 ml - rituxan is indicated for the treatment of adult patients with: - relapsed or refractory, low-grade or follicular, cd20-positive, b-cell nhl as a single agent. - previously untreated follicular, cd20-positive, b-cell nhl in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy. - non-progressing (including stable disease), low-grade, cd20-positive, b-cell nhl as a single agent after first-line cyclophosphamide, vincristine, and prednisone (cvp) chemotherapy. - previously untreated diffuse large b-cell, cd20-positive nhl in combination with cyclophosphamide, doxorubicin, vincristine, prednisone (chop) or other anthracycline-based chemotherapy regimens. rituxan is indicated for the treatment of pediatric patients aged 6 months and older with: - previously untreated, advanced stage, cd20-positive diffuse large b-cell lymphoma (dlbcl), burkitt lymphoma (bl), burkitt-like lymph

Israel - English - Ministry of Health

roche pharmaceuticals (israel) ltd - rituximab - concentrate for solution for infusion - rituximab 10 mg/ml - rituximab - rituximab - mabthera is indicated for the following indications: * non-hodgkin’s lymphoma (nhl)mabthera is indicated for the treatment of patients with relapsed or refractory low-grade or follicular, b-cell non-hodgkin’s lymphoma.mabthera is indicated for the treatment of previously untreated patients with low-grade or follicular lymphoma in combination with chemotherapy mabthera is indicated for the treatment of patients with cd20 positive diffuse large b-cell non-hodgkin's lymphoma in combination with chop chemotherapy. mabthera maintenance therapy is indicated for the treatment of follicular lymphoma patients responding to induction therapy. * chronic lymphocytic leukaemia (cll)mabthera in combination with chemotherapy is indicated for the treatment of patients with previously untreated and relapsed/refractory chronic lymphocytic leukaemia. only limited data are available on efficacy and safety for patients previously treated with monoclonal antibodies including mabthera or patients refractory to previous mabthera plus chemotherapy.* rheumatoid arthritismabthera is indicated, in combination with methotrexate, to reduce signs and symptoms in adult patients with moderately to severely active rheumatoid arthritis who had an inadequate response or intolerance to one or more tnf antagonist therapies.* granulomatosis with polyangiitis and microscopic polyangiitismabthera, in combination with glucocorticoids, is indicated for the treatment of adult patients with granulomatosis with polyangiitis (gpa) (wegener’s granulomatosis (wg) and microscopic polyangiitis (mpa). *pemphigus vulgarismabthera is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris (pv).

Australia - English - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - rituximab, quantity: 1600 mg - injection - excipient ingredients: vorhyaluronidase alfa; histidine; histidine hydrochloride; trehalose dihydrate; methionine; polysorbate 80; water for injections - mabthera sc 1600 mg is indicated for the treatment of patients with cd20 positive chronic lymphocytic leukaemia (cll) in combination with chemotherapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - rituximab, quantity: 1400 mg - injection - excipient ingredients: vorhyaluronidase alfa; histidine; histidine hydrochloride; trehalose dihydrate; methionine; polysorbate 80; water for injections - mabthera sc is indicated for treatment of patients with: - cd20 positive, previously untreated, stage iii/iv follicular, b-cell non-hodgkin's lymphoma, - cd20 positive, relapsed or refractory low grade or follicular, b-cell non-hodgkin's lymphoma, - cd 20 positive, diffuse large b-cell non-hodgkin's lymphoma, in combination with chemotherapy.

Kenya - English - Pharmacy and Poisons Board

amring farma s.r.l. blvd. mircea eliade 7, sector 1, bucuresti, - rituximab - concentrate for solution for infusion - 10mg/ml - rituximab

Australia - English - Department of Health (Therapeutic Goods Administration)

celltrion healthcare australia pty ltd - rituximab, quantity: 100 mg - injection, concentrated - excipient ingredients: polysorbate 80; water for injections; sodium chloride; sodium citrate dihydrate - non-hodgkin?s lymphoma truxima is indicated for treatment of patients with: -cd20 positive, previously untreated, stage iii/iv follicular, b-cell non-hodgkin?s lymphoma; - cd20 positive, relapsed or refractory low grade or follicular, b-cell non-hodgkin's lymphoma; - cd20 positive, diffuse large b-cell non-hodgkin?s lymphoma, in combination with chemotherapy.,chronic lymphocytic leukaemia truxima is indicated for the treatment of patients with cd20 positive chronic lymphocytic leukaemia (cll) in combination with chemotherapy.,rheumatoid arthritis truxima (rituximab) in combination with methotrexate is indicated for the treatment of adult patients with severe, active rheumatoid arthritis who have had an inadequate response or intolerance to at least one tumour necrosis factor (tnf) inhibitor therapy. truxima has been shown to reduce the rate of progression of joint damage as measured by xray when given in combination with methotrexate.,granulomatosis with polyangiitis (wegener?s) (gpa) and microscopic polyangiitis (mpa) truxima in combination with glucocorticoids is indicated for the induction of remission in patients with severely active granulomatosis with polyangiitis (gpa, also known as wegener?s granulomatosis) and microscopic polyangiitis (mpa). the efficacy and safety of retreatment with rituximab have not been established.

Australia - English - Department of Health (Therapeutic Goods Administration)

celltrion healthcare australia pty ltd - rituximab, quantity: 500 mg - injection, concentrated - excipient ingredients: sodium citrate dihydrate; polysorbate 80; water for injections; sodium chloride - non-hodgkin?s lymphoma truxima is indicated for treatment of patients with: -cd20 positive, previously untreated, stage iii/iv follicular, b-cell non-hodgkin?s lymphoma; - cd20 positive, relapsed or refractory low grade or follicular, b-cell non-hodgkin's lymphoma; - cd20 positive, diffuse large b-cell non-hodgkin?s lymphoma, in combination with chemotherapy.,chronic lymphocytic leukaemia truxima is indicated for the treatment of patients with cd20 positive chronic lymphocytic leukaemia (cll) in combination with chemotherapy.,rheumatoid arthritis truxima (rituximab) in combination with methotrexate is indicated for the treatment of adult patients with severe, active rheumatoid arthritis who have had an inadequate response or intolerance to at least one tumour necrosis factor (tnf) inhibitor therapy. truxima has been shown to reduce the rate of progression of joint damage as measured by xray when given in combination with methotrexate.,granulomatosis with polyangiitis (wegener?s) (gpa) and microscopic polyangiitis (mpa) truxima in combination with glucocorticoids is indicated for the induction of remission in patients with severely active granulomatosis with polyangiitis (gpa, also known as wegener?s granulomatosis) and microscopic polyangiitis (mpa). the efficacy and safety of retreatment with rituximab have not been established.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - rituximab, quantity: 10 mg/ml - injection, concentrated - excipient ingredients: sodium chloride; citric acid monohydrate; hydrochloric acid; water for injections; sodium hydroxide; polysorbate 80 - non-hodgkin?s lymphoma (nhl),riximyo (rituximab) is indicated for treatment of patients with:,? cd20 positive, previously untreated, stage iii/iv follicular, b-cell non-hodgkin?s lymphoma,,? cd20 positive, relapsed or refractory low grade or follicular, b-cell non-hodgkin's lymphoma,,? cd20 positive, diffuse large b-cell non-hodgkin?s lymphoma, in combination with chemotherapy.,chronic lymphocytic leukaemia (cll),riximyo (rituximab) is indicated for the treatment of patients with cd20 positive chronic lymphocytic leukaemia in combination with chemotherapy.,rheumatoid arthritis (ra),riximyo (rituximab) in combination with methotrexate is indicated for the treatment of adult patients with severe, active rheumatoid arthritis who have had an inadequate response or intolerance to at least one tumour necrosis factor (tnf) inhibitor therapy. rituximab has been shown to reduce the rate of progression of joint damage as measured by x-ray when given in combination with methotrexate.,granulomatosis with polyangiitis (wegener?s) (gpa) and microscopic polyangiitis (mpa),riximyo (rituximab) in combination with glucocorticoids is indicated for the induction of remission in patients with severely active granulomatosis with polyangiitis (gpa, also known as wegener?s granulomatosis) and microscopic polyangiitis (mpa). the efficacy and safety of retreatment with rituximab have not been established.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - rituximab, quantity: 10 mg/ml - injection, concentrated - excipient ingredients: water for injections; polysorbate 80; citric acid monohydrate; hydrochloric acid; sodium chloride; sodium hydroxide - non-hodgkin?s lymphoma (nhl),riximyo (rituximab) is indicated for treatment of patients with:,? cd20 positive, previously untreated, stage iii/iv follicular, b-cell non-hodgkin?s lymphoma,,? cd20 positive, relapsed or refractory low grade or follicular, b-cell non-hodgkin's lymphoma,,? cd20 positive, diffuse large b-cell non-hodgkin?s lymphoma, in combination with chemotherapy.,chronic lymphocytic leukaemia (cll),riximyo (rituximab) is indicated for the treatment of patients with cd20 positive chronic lymphocytic leukaemia in combination with chemotherapy.,rheumatoid arthritis (ra),riximyo (rituximab) in combination with methotrexate is indicated for the treatment of adult patients with severe, active rheumatoid arthritis who have had an inadequate response or intolerance to at least one tumour necrosis factor (tnf) inhibitor therapy. rituximab has been shown to reduce the rate of progression of joint damage as measured by x-ray when given in combination with methotrexate.,granulomatosis with polyangiitis (wegener?s) (gpa) and microscopic polyangiitis (mpa),riximyo (rituximab) in combination with glucocorticoids is indicated for the induction of remission in patients with severely active granulomatosis with polyangiitis (gpa, also known as wegener?s granulomatosis) and microscopic polyangiitis (mpa). the efficacy and safety of retreatment with rituximab have not been established.